

Clinically Assisted Hydration in Palliative Care

Version	Date	Purpose of Issue/Description of Change	Review Date
1	May 2016	New Guideline Based on Saint Michael's Hospice, Clinical Guidelines for Clinically Assisted Hydration Nov 2015.	May 2018
2	September 2017	Updated due to changes to the Community Care Teams	September 2019
Status		Open	
Publication Scheme		No Listing	
FOI Classification		Release without reference to author	
Function/Activity		Palliative Care	
Record Type		Policy	
Key Words		Subcutaneous fluids, clinically assisted hydration, palliative care	
Standard			
Author		Annette Clark, Liz Brown, Kath Lambert	Date/s
Approval and/or Ratification Body		Area Prescribing Committee Clinical Risk Management Group	June 2016

Contents

1.	AIM	3
2.	PRE-REQUISITE QUALIFICATIONS/EXPERIENCE	3
2.1.	Education and Training.....	4
2.2.	Assessment of Competence.....	4
3.	GUIDELINES FOR THE ADMINISTRATION OF CLINICALLY ASSISTED HYDRATION IN PALLIATIVE CARE.....	4
3.1.	Indications for use	4
3.2.	Choice of route	6
3.3.	Advantages over the IV route	6
3.4.	Contra-Indications	7
3.5.	Equipment Required.....	7
3.6.	Prescribing.....	8
3.6.1.	Fluids that may be given via subcutaneous administration.....	8
3.6.2.	Fluids that should not be given via subcutaneous administration.....	8
3.6.3.	Volume of fluid.....	9
3.7.	Preparing the patient and family	9
3.8.	Skin site selection and insertion of Saf-T-Intima.....	9
3.9.	Siting the subcutaneous cannula (Saf-T-Intima).....	10
3.10.	Practical considerations for setting up the subcutaneous fluid infusion	11
3.11.	Recommended infusion rates and calculating drop rate.....	12
3.12.	Commencing the infusion	13
3.13.	Monitoring.....	14
4.	DISSEMINATION AND IMPLEMENTATION	15
5.	MONITORING COMPLIANCE AND EFFECTIVENESS.....	15
6.	REFERENCES	15
7.	APPENDIX 1: CONSULTATION SUMMARY	19
8.	APPENDIX 2: ASSESSMENT OF COMPETENCY DOCUMENT	20
9.	APPENDIX 3: SUBCUTANEOUS FLUID SITE MONITORING CHART ...	21

INTRODUCTION

This guideline covers Harrogate and District NHS Foundation Trust (HDFT) both hospital and community and is based on Saint Michael's Hospice Guidelines for Clinically Assisted Hydration (2015)

These guidelines have been written in response to the NICE guidelines: Intravenous fluid therapy in adults in hospital, Dec 2013 and "One Chance to Get it Right", the document produced by the Leadership Alliance for the Care of Dying People in June 2014 in response to the independent Liverpool Care Pathway (LCP) review in July 2013 and the NICE guidelines for the care of dying adults in the last days of life 2015.

Clinically assisted hydration (CAH) is the current term used by the GMC for the provision of fluid non-orally and in this guideline refers to subcutaneous fluids only.

The administration of subcutaneous fluids can provide a safe and effective way of clinically assisting with hydration and symptom control for palliative care patients who are unable to take, or absorb, adequate oral fluids and who require a constant therapeutic infusion. It is also a relatively safe, reliable and cost effective method and is suitable for the use in community.

1. AIM

The aim of this guideline is to provide a framework to ensure that patients who require the CAH receive safe and effective care.

2. PRE-REQUISITE QUALIFICATIONS/EXPERIENCE

This guideline applies to all nurses with a valid NMC registration, working with adults in hospital and community settings and working within the NMC Code (2015): The Code Professional standards of practice and behavior for nurses and midwives. Standards for Medicines Management (NMC 2008) and Record Keeping: Guidance for Nurses and Midwives (NMC 2009) and have undertaken the required training and are competent to administer fluids via the subcutaneous route.

Registered Nurses who have previously undertaken this role outside HDFT may continue to practice with the approval of their line manager, as long as they can provide evidence of previously approved training and assessment and can submit evidence of continuing competence.

2.1. Education and Training

All nurses undertaking this role must attend CAH training (unless previously trained outside HDFT – see above) and undertake a self-assessment of competency (Appendix 2) before undertaking this procedure.

2.2. Assessment of Competence

All registered nurses have a responsibility to assess their own competence in accordance with the NMC (2015): The Code Professional standards of practice and behavior for nurses and midwives.

HDFT nurses are also required to demonstrate competence by assessment against the criteria specified on the competency checklist. The assessor must be a registered nurse who has completed the training and is competent in the administration of subcutaneous fluids. The nurse should maintain evidence of their competence and practice in their own professional profile and ensure they attend refresher training when require to ensure competence.

3. GUIDELINES FOR THE ADMINISTRATION OF CLINICALLY ASSISTED HYDRATION IN PALLIATIVE CARE

3.1. Indications for use

The decision to administer fluids subcutaneously needs to be taken by the multidisciplinary team - in consultation with the patient and their carers - and when other methods of administration e.g. oral, intravenous, nasogastric have been discounted.

There is considerable debate and opinion in the literature about the pros and cons of CAH in terminal care. Very few patients admitted to a hospice inpatient setting in the UK will receive intravenous or subcutaneous fluids, despite the fact that most are, or become, unable to maintain a pre morbid adequate fluid intake. Whilst considered controversial by some, this is standard care in the UK, due to the lack of evidence of benefit in dying people and the underlying ethos of palliative care to regard dying as a normal process and its intention to neither hasten nor postpone death. However, there is a lack of good research evidence to support either the giving or withholding of parenteral fluids. The evidence around symptom management is also limited.

It should also be noted that a blanket policy of clinically assisted nutrition or hydration, or of no clinically assisted nutrition or hydration, is ethically indefensible and in patients lacking capacity prohibited under the MCA 2005.

Palliative care is ever evolving, now providing care for patients who have a terminal illness of any diagnosis, at any stage in their illness and appropriate treatment is determined by the patient alongside the clinical team. Therefore CAH is increasing in frequency as we care for more patients who are not imminently dying or who wish to pursue a more aggressive treatment if their clinical team agrees that it is neither futile nor detrimental to their health. CAH is a medical treatment and therefore cannot be demanded by patient or family if considered futile.

In giving CAH we need to ensure that we are using the correct fluids, in the correct volume, in the most effective and acceptable way. Whilst the NICE guidelines are written for use in hospital and pertain to intravenous fluids only, they contain important guidance on prescribing fluids relevant to the adult palliative care population and to subcutaneous fluid therapy.

It should be noted that the Liverpool Care Pathway review panel found that most of the critical submissions it received from families included concerns around hydration and nutrition. The finding that these issues are of such concern to patients and families at the end of life is not new. These issues should be specifically discussed as part of every patient's individualised care. Fluids are commonly regarded as basic care and a fundamental human need, synonymous with life, compassion, care and nurture so it can be seen why the lack of provision of CAH causes distress. Additionally some families may perceive dehydration to be the direct cause of suffering and death. Whilst no reference in the response is made to CAH, it is reinforced that it is the clinical team's duty to ensure that hydration is being provided that meets the patient's needs.

It is assumed, therefore, that health care professionals will use professional knowledge, ethical standards and clinical judgment appropriate to their role in applying this procedure in the management of patient care.

Subcutaneous fluids may be indicated in the maintenance of short term hydration in patients:

- who are unable to take adequate fluids orally and are thirsty and have a persistent dry mouth despite exemplary mouth care
- who have excessive fluid loss with acute dehydration from a reversible cause when felt to be clinically appropriate e.g. profuse infective diarrhoea in a patient who is not dying
- who are mildly or moderately dehydrated, usually indicated by urea and electrolyte imbalance, or as part of the treatment of hypercalcaemia

- in whom it is difficult, impractical or inappropriate to insert an intravenous (IV) line
- who are liable to live for some time where it would be unethical to deprive them of fluid
- who have capacity and make an informed choice to continue artificial hydration
- who want life prolonging treatment when swallowing is compromised due to a local cause whilst a more permanent route is explored.
- with delirium where dehydration or opioid toxicity is felt to be a cause.
- who are clearly dying, and when a trial of fluids at either the patient or family's request could be considered if the lack of fluids is felt to be causing considerable distress despite discussion of the evidence and if it is not detrimental to the patient's health. However it should be remembered that CAH is a medical treatment and if considered futile cannot be demanded. It may be worth seeking a second opinion or suggesting MDT discussion if a clinician feels this treatment is futile but a family feel strongly that it should be offered.

3.2. Choice of route

The subcutaneous route is preferable to intravenous, except in the following circumstances:

- volume of fluid required is more than can be given subcutaneously, usually approx. 1L in 24 hours although higher volumes have been given
- there is already intravenous access via a cannula /Hickman /PICC line or planned access by one of these routes to enable intravenous medication to be given
- potassium replacement is required

3.3. Advantages over the IV route

- subcutaneous fluids are less likely to cause fluid overload or pulmonary oedema
- insertion of subcutaneous cannula is less distressing to the patient
- subcutaneous fluids do not cause thrombophlebitis
- subcutaneous fluids have not been shown to cause septicemia or systemic infection
- subcutaneous fluids can be set up and administered by nurses in almost any setting

3.4. Contra-Indications

Subcutaneous fluids should not be considered in the following circumstances:

- Patients needing rapid administration of fluids e.g. shock, circulatory failure, severe dehydration
- Patients who express a wish for more active medical management e.g. iv fluids
- Patients with clotting disorders
- Patients who have problems with fluid overload, e.g. congestive cardiac failure, marked oedema or renal failure
- Patients where precise control of fluid balance is clinically important
- Patients who require more than 2 litres of fluid in a 24 hour period
- Patients with severe electrolyte disturbance.

3.5. Equipment Required

For insertion of saf-t-intima and the administration of subcutaneous fluids:

1. Fluids Replacement Therapy Chart (WHZ066) available via the Community Care Team based at Crimple Court, Hornbeam Park or will be supplied with patient if discharged from HDFT on CAH.
2. Subcutaneous fluid site monitoring sheet (see Appendix 3) also available via Community Care Team or will be supplied with patient if discharged from HDFT on CAH.
3. Prescribed infusion fluid (0.9% Sodium Chloride) available via HDFT inpatient pharmacy department. Call in advance to order and they will ensure the fluid is available to collect. If the patient is being discharged from HDFT a box of fluid will be supplied on discharge containing 12 bags of fluid.
4. Saf-T-Intima subcutaneous cannula
5. Standard intravenous administration giving set available via the Community Care Team
6. A semi-permeable transparent adhesive film dressing
7. Sharps container
8. Single use disposable non-sterile gloves
9. Single use disposable apron
10. Bionector
11. Stand for the administration of fluids available via Community Care Team
12. 2% Chlorhexidine/70% alcohol impregnated wipe
13. Water for injection

For the removal of cannula:

1. Single use disposable non-sterile gloves
2. Single use disposable apron

3. Suitable sterile dressing
4. Sharps container

3.6. Prescribing

- An appropriately qualified medical practitioner or registered independent prescriber is responsible for prescribing the fluids. If the patient is known to the Palliative Care Team a multi-disciplinary discussion and agreement that CAH is in the patient's best interests should be held prior to these being commenced. The Palliative Care Team is available for advice/consultation if required.
- A recent urea and electrolyte result may aid decision making for CAH and whether IV fluids may be more appropriate. If normal urea and electrolyte results and patient is not clinically dehydrated then explanations about the use and limitations of CAH may avoid false expectations for patients and families.
- Nurses must check that medication has been legally prescribed before administration.
- A risk assessment should be undertaken prior to prescribing and commencement of the subcutaneous fluids.
- A patient who requires subcutaneous fluids at home should have someone staying with them at all times.
- Up to two litres of fluid a day may be administered subcutaneously i.e. maximum rate is 1 litre over 12 hrs. If the patient is able to take oral fluids, then one litre subcutaneously over 24 hours may be sufficient.
- Subcutaneous fluids should be administered using gravity only; mechanical devices should not be used. (RCN 2005).
- A Harrogate and District Foundation Trust Fluid Replacement Therapy Chart (WHZ066) should be used to prescribe the subcutaneous fluids on the fluid replacement page stating that fluids should be administered subcutaneously See appendix 4. Fluids cannot be prescribed on an FP10.
- A subcutaneous fluid site monitoring sheet should be used to monitor administration and the site of the cannula. See appendix 3.
- Fluids can be administered continuously or over smaller periods of time if more convenient for the patient.

3.6.1. Fluids that may be given via subcutaneous administration

Parenteral fluids should be tailored to the clinical indication for which they are required, the route they will be given via and the individual patient. 0.9% Sodium Chloride is the recommended fluid for subcutaneous use and should be prescribed in either 500ml or 1000ml volumes.

3.6.2. Fluids that should not be given via subcutaneous administration

- Colloids
- Blood or blood products

- Total parental nutrition (TPN)
- Solutions with added medication
- Glucose solutions > 5%
- Solutions containing potassium

3.6.3. Volume of fluid

Daily fluid volume requirements should be calculated using the guidance below

- 25-30 ml/kg/day normal population (obese patients use ideal body weight)
- 20-25ml/kg/day if older, frail, renal imp, cardiac failure, malnourished

Palliative care patients can be malnourished and frail. In addition they often have low albumin levels and increased levels of ADH with a tendency to retain water. Therefore, unless there is good reason, they should not be given more than 20ml/kg/day including oral intake of fluid/medications etc. Lesser volumes are acceptable if the aim of treatment is not simply replacing daily volume requirements e.g. treatment of a dry mouth, or if there are signs of fluid overload and a more cautious approach is required.

Within research literature the volume of subcutaneous fluids given is often 1.5 – 2L/day using varying rates. There are small studies that report patients who have tolerated boluses up to 500ml/hr.

3.7. Preparing the patient and family

Explain the procedure, indications and aims of subcutaneous fluids to the patient and/or relatives. This is to remove any misconceptions around the use of subcutaneous fluids, advising them that they are used only to alleviate symptoms when the patient is unable to swallow oral fluids and IV fluids are inappropriate or impractical. They should be informed that ongoing blood monitoring may be required once fluids are commenced to monitor effects. This discussion and reasoning should be clearly documented.

3.8. Skin site selection and insertion of Saf-T-Intima

The best sites to use for subcutaneous infusion of fluids are the lateral aspects of the upper arms and thighs, the anterior chest below the clavicle and occasionally, the back or abdomen (Graham 2006).

Areas which should **not** be used are:-

- Lymphoedematous limbs, e.g. avoid arms on the same side as previous breast/axillary surgery. A cannula breaches skin integrity, thus increasing the risk of infection in a limb which is already susceptible
- Abdomen when distended by ascites or abdominal disease
- Sites over bony prominences. The amount of subcutaneous tissue will be diminished, impairing the rate of absorption
- Previously irradiated skin area. Radiotherapy can cause sclerosis of small blood vessels, thus reducing skin perfusion
- Sites near a joint; excessive movement may cause cannula displacement and patient discomfort

Sites should be rotated and giving sets changed every 5 days or before if any signs of site reaction to minimise tissue damage (see monitoring section 3.13.).

If the patient is on artificial hydration for longer than 5 days the patient should be reviewed by their GP who may need to check urea and electrolytes to avoid over hydration.

3.9. Siting the subcutaneous cannula (Saf-T-Intima)

- Explain and discuss the procedure with the patient/family to obtain informed consent
- Wash hands with soap and water or alcohol hand rub and assemble required equipment
- Expose the chosen site for infusion
- Clean site for a minimum of 30 seconds with a 2% Chlorhexidine/70% alcohol impregnated wipe and allow to dry naturally
- Hold the wings on the Saf-T-Intima between the thumb and ring finger extending the tubing straight whilst holding the 'Y' port in the same hand. Rotate the white base through 360 degrees (i.e. one full turn) in order to break the seal over the 'needle introducer' within the subcutaneous catheter – you should see the needle rotate within the catheter
- Grasp pebbled side of wings of the Saf-T-Intima pinching wings firmly together to lock the needle in place
- Insert the Saf-T-Intima needle subcutaneously up to a 45 degree angle
- Open the wings flat against the skin (pebble side down)
- Apply transparent dressing over the insertion site and the wings of the cannula

- Apply firm fingertip pressure over the wings of the cannula (avoiding the centre where the needle retracts) and simultaneously grasp the pebbled end of the white shield and pull in a **straight** continuous motion until the needle has fully withdrawn into the cylinder
- Gently remove the cylinder from the cannula port (if it has not released spontaneously) exposing the adaptor with the rubber bung
- Place the needle shield in the sharps container
- If blood appears in the line on insertion of the needle, withdraw immediately and repeat the process at another site with a new cannula
- Prime the Saf-T-Intima with 0.2 ml of water for injection
- If necessary secure cannula tubing with a small strip of tape just above the Y connection (when sited on a limb, secure to the front of the limb to aid comfort)
- Change the rubber bungs for Bionector adaptors. Document the siting and date of insertion on the invasive devices connection record
- Wash and dry hands thoroughly and use alcohol hand rub in accordance with Infection Control Policy

3.10. Practical considerations for setting up the subcutaneous fluid infusion

- Subcutaneous fluids should ideally be prescribed and commenced in normal working hours. The on-call team or OOH service should not be expected to make a decision to commence subcutaneous fluids. If it is likely the patient will require subcutaneous fluids then a decision should ideally be made within normal working hours and communicated to the out of hours team. OOH teams should only prescribe fluids if this decision cannot wait until the next working day.
- If fluids are in place overnight and/or on a weekend then the on-call team or OOH service and the Out of Hours Nursing Service should be informed to ensure continuity of care. .
- If the fluids are likely to be administered for a period of time in the community setting, a family member can be taught how to monitor and discontinue the infusion especially if this is not going to occur in normal working hours.
- The patient may be in hospital and need to continue subcutaneous fluids following discharge or may start subcutaneous fluids to address their needs in their "home" setting. This could be a residential or nursing home setting, or the patient's own home. If this is required adequate communication and preparation time should be arranged with the community team to support a safe, effective discharge. This is especially necessary if training of community or nursing home staff involved in the patients care is required.

- If continuing overnight in community, medical and nursing advice can be sought if required from the Out of Hours GP service, Out of Hours Nursing Service or Saint Michaels Hospice inpatient unit.
- Registered nurses are responsible for the administration of subcutaneous fluids and will support and guide the non-registered staff.

It is recognised that there will be differing levels of competence in any given care setting, particularly where subcutaneous fluids have not been used and are being newly introduced or used infrequently. The decision to administer subcutaneous fluids in a community setting should only be made AFTER all of the following are assured and in place:

- An ongoing commitment to prescribe, monitor and review subcutaneous fluids for as long as they are appropriate, is given by the patient's general practitioner
- A clear clinical decision is recorded and committed to by medical staff
- Fluids are sourced and ordered through HDFT pharmacy on the production of a fluid replacement therapy chart prescription form (WHZ066)
- Suitably competent personnel are available to administer and monitor the infusion and evaluate the process or training has been completed to enable this to proceed.
- Equipment for the administration of subcutaneous fluids including drip stand and giving sets are ordered and collected from Community Care Team base at Crimple Court, Hornbeam Park.

3.11. Recommended infusion rates and calculating drop rate

The fluid is infused by gravity and there is no need for a pump to regulate administration.

To set up a manually controlled drip accurately by eye, you need to be able to count the number of drops per minute, which will equate to the amount prescribed. The formula for calculation is:

$$\text{RATE} = \frac{\text{VOLUME (IN DROPS)}}{\text{TIME (IN MINUTES)}}$$

To calculate the volume in drops, you need to know how many drops of the fluid ordered are contained in one millilitre (ml). You should find this information on the packaging of the administration set.

The volume in mls is then multiplied by the number of drops per ml to give the volume in drops. Similarly to find the rate in minutes, you need to change the hours into minutes, by multiplying by 60 Hutton (1998).

Two common sizes are 20 drops per ml and 15 drops per ml.

Examples:

$$\frac{1000\text{mls (volume of infusion)} \times \mathbf{20 \text{ (drops)}}}{12 \text{ (hrs)} \times 60 \text{ (mins)}} = \frac{20,000}{720} = 28 \text{ drops}$$

$$\frac{1000\text{mls (volume of infusion)} \times \mathbf{15 \text{ (drops)}}}{12 \text{ (hrs)} \times 60 \text{ (mins)}} = \frac{15,000}{720} = 21 \text{ drops}$$

NB. Since we are trying to work out a number of drops, it is sensible to round up to a whole number.

3.12. Commencing the infusion

- Prepare the patient and give full explanations to gain informed consent where possible
- Establish that the patient has no known allergies, check in the patient's records and also ask the patient/family
- Ensure the patient is comfortable and maintain privacy and dignity
- Check the prescription is for the correct patient and clearly states the patient's full demographic details
- Check the name, strength and volume of the infusion fluid against the prescription chart
- Check the expiry date of the infusion bag
- Check the packaging is intact and inspect the container and contents in a good light for cracks or punctures
- Inspect the fluid for discoloration, haziness and crystalline or precipitate matters
- Calculate the correct drip rate setting using the drop calculation formula
- Decontaminate hands
- Apply single use disposable apron and gloves
- Prime the administration set with the infusion fluid and connect to the Saf-T-intima via the Bionector
- Commence the infusion and adjust the drops per minute to the correct length of time for the infusion as per prescribed rate of infusion

- Label the administration set with the date and time of commencement and document in the patient notes, recording batch number and expiry date on the fluid replacement therapy chart
- Clear away all equipment and dispose of clinical waste as per trust policy
- Decontaminate hands
- Monitor patient's general condition and continue to monitor urea and electrolytes if appropriate to do so as dictated by the prescriber or Palliative Care Team
- Review on an ongoing basis the appropriateness to continue, effects and sides effects and impact on symptoms
- Discuss all findings with the patient/family to ensure they understand rationale for continuing or discontinuing subcutaneous fluid administration

3.13. Monitoring

Community - the infusion will be monitored at each nurse visit. This should be a minimum of once daily. Patients and carers will be given help and support on how to monitor the infusion. They will be encouraged to discuss with the district nurse if they have any comments or concerns.

Hospital - In hospital, the infusion should be monitored 2 - 4 hourly.

It is important that the effectiveness of symptom control is also closely monitored and recorded.

See appendix 3 for monitoring chart.

Side effects of administration of subcutaneous fluids – if any of these occur, stop the infusion discuss the appropriateness for continuing the infusion with the GP
If the infusion is to continue re-site the Saf-T-Intima:

- Pain/tenderness
- Bruising/bleeding
- Local oedema
- Erythema
- Local inflammation or infection
- Signs of fluid overload i.e. dyspnoea, peripheral oedema
- Leakage at site
- Abscess formation

Discuss with the Palliative Care Team and prescribing practitioner whether the infusion should continue if sites need frequent changes or consider the addition of Hyaluronidase to aid the absorption of the infusion.

Poor Absorption

Hyaluronidase is an enzyme that has a temporary and reversible depolymerising effect on the polysaccharide hyaluronic acid, which is present in the intercellular matrix of connective tissue. It can help improve absorption of subcutaneous fluids. 1500iu of Hyaluronidase is dissolved in 1ml of water for injection or 0.9% sodium chloride and injected into the site before the infusion is set up, or injected into the tubing of the infusion set, about 2cm back from the needle at the start of the infusion. This should be prescribed on the community palliative care medication chart in the regular/prn medication section (WHZ061) An FP10 will be required to obtain this from a community pharmacy. 1500iu is sufficient for administration of 500-1000ml of most fluids.

4. DISSEMINATION AND IMPLEMENTATION

This procedure has been circulated to the consultation group as listed in Appendix 1. Following approval and ratification it will be available on the intranet for staff to view. It will also be circulated via email to all GP's. Members of the Palliative Care Team, matrons and ward managers will ensure implementation of the guidelines and will educate staff on its existence as appropriate.

5. MONITORING COMPLIANCE AND EFFECTIVENESS

Competency assessments will be completed for each individual qualified nurse who will carry out this procedure.

Practice will be compared to the standards within this procedure using clinical audit.

Incidents and complaints relating to subcutaneous fluid administration should be reported on a Datix form and be reviewed to determine areas for learning.

6. REFERENCES

Cerchietti L et al (2000). Hypodermoclysis for control of dehydration in terminal-stage cancer. *International Journal of Palliative Nursing* 6:370-4

Constans T et al (1991) Hypodermoclysis in dehydrated elderly patients: local effects with and without hyaluronidase. *Journal of Palliative Care* 7:10-12

Craig G. (1994) On withholding and nutrition in the terminally ill: has palliative medicine gone too far? *Journal of Medical Ethics*; 20: 139 – 143.

DoH (2013) More Care, Less Pathway. A Review of the Liverpool Care Pathway,

DoH (2014) One Chance to get it Right; Improving people's experience of care in the last few days and hours of life, Leadership Alliance for the Care of Dying People, <https://www.gov.uk/government/publications/liverpool-care-pathway-review-response-to-recommendations>

Donnelly M (1999) The benefits of hypodermoclysis. *Nursing Standard* 13(52), 44-5.

Dougherty L. & Lister S. (2011) *The Royal Marsden Hospital Manual of Clinical Nursing Procedures*, 8th Edition. John Wiley and Sons Ltd, Oxford.

Ellershaw JE et al (1995) Dehydration and the dying patient. *Journal of Pain and Symptom Manage* 10 (3) 192-7

Fainsinger R et al. (1994) The management of dehydration in terminally ill patients. *Journal of Palliative Care*; 10(3): 55-59.

Fainsinger R L et al (1994) The use of hypodermoclysis for rehydration in terminally ill cancer patients. *Journal of Pain and Symptom Management* 9 (5):298-302

Ferrand S. & Campbell A. J. (1996) Safe, Simple Subcutaneous fluid administration. *British Journal of Hospital Medicine* Vol. 55 No. 11.

Good P et al (2014) Medically assisted hydration for adult palliative care patients (review) *The Cochrane Library* 2014

Graham, F. (2006) Syringe Drivers and Subcutaneous sites: a review. *European Journal of Palliative Care*, 13(4)

Gray R. (1999) To Hydrate or Not To Hydrate. *Nursing Times* 95 No 23 32 – 33

Harrogate and District Foundation NHS Trust. (2010). Safe Use of Injectable Medicines Policy. [Online]. [Accessed 24 September 2015]. Available from: <http://www.hdft.nhs.uk/documents/policies/>

Harrogate and District Foundation NHS Trust. (2011). Hickman lines Professionals guide. [Online]. [Accessed 24 September 2015]. Available from: <http://www.hdft.nhs.uk/documents/policies/>

Harrogate and District Foundation NHS Trust. (2014). PICC line Professionals guide. [Online]. [Accessed 24 September 2015]. Available from: <http://www.hdft.nhs.uk/documents/policies/>

Harrogate and District Foundation NHS Trust. (2014-2015). Community Infection Prevention and Control. [Online]. [Accessed 24 September 2015]. Available from: <http://www.infectionpreventioncontrol.co.uk/resources/type/policies>

Harrogate and District Foundation NHS Trust. (2015). CVAD Policy HDFT Haem/onc 2015. [Online]. [Accessed 24 September 2015]. Available from: <http://www.hdft.nhs.uk/documents/policies/>

Hays H (1985) Hypodermoclysis for symptom control in terminal care. *Canadian Family Physician* 31 1253 -2156.

<https://www.gov.uk/government/publications/review-of-liverpool-care-pathway-for-dying-patients>

Hutton, M. (1998) Numeracy skills for intravenous calculations. *Nursing Standard*, July 15 Vol. 12 No. 43.

Khan, M. & Younger, G. (2007) Promoting safe administration of subcutaneous infusions. *Nursing Standard*, Vol. 21 No. 31 p 50 – 56.

Krishna L. (2010) “Artificial hydration at the end of life in an Oncology Ward in Singapore” *Indian Journal of Palliative Care* 16(3):168-173

McCann R.M. et al. (1994) Comfort care for terminally ill patients: the appropriate use of nutrition and hydration. *JAMA*; 272: 1263 – 66.

Morita T, Hyodo I, Yoshima T, Ikenaga M et al. (2006) Artificial hydration therapy, laboratory findings and fluid balance in terminally ill patients with abdominal malignancies. *Journal of Pain and Symptom Management*; 31(2); 130 – 138.

Musgrave C.F. et al (1995) “The sensation of thirst in dying patients receiving IV hydration” *Journal of Palliative Care* 11(4):17-21
National Council for Hospice and Specialist Palliative Care Services (1997). *Ethical decision making in Palliative care: Artificial hydration for people who are terminally ill*. NCHSPC (www.hospice-spc-council.org.uk).

NICE (2013) *Intravenous Fluid Therapy in Adults in Hospital*. Nice clinical guideline 174. guidance.nice.org.uk/cg174

NMC (2010) *Standards for Medicines Management* London. www.nmc-uk.org/standards/additional-standards/standards-for-medicines-management/

NMC (2015) *The Code Professional standards of practice and behaviour for nurses and midwives*. Published 29 January 2015, Effective from 31 March 2015 www.nmc-uk.org/code.

O’Keefe S.T. and Lavan J.N. (1996) Subcutaneous fluids in elderly hospital patients with cognitive impairment. *Gerontology* 42, 36 – 39.

Patchett M. (1998). Providing hydration for the terminally ill patient. *International Journal of Palliative Nursing*, Vol. 4 No. 3.

Royal College of Nursing (2010) *Standards for infusion therapy*. www.rcn.org.uk

Sasson M. & Shvartzman P. (2001) Hypodermoclysis: An alternative infusion technique. *American Family Physician*. Nov. 1 Vol. 64 No. 9.

Smith J.C., Roberts A., Moorhead L., Smith K., Tate T. (2010) Guidelines for the use of Hydration in Dying Patients. Standards and guidelines: Fourth Edition. Merseyside and Cheshire Palliative Care Network Audit Group.

Steiner N. et al. (1998) Methods of hydration in palliative care patients. Journal of Palliative Care; 6 – 13.

The National Council for Palliative Care (NCPC) and the Association for Palliative Medicine (2007) Artificial Nutrition & Hydration: Guidance in End of Life Care for Adults

Turner T, Cassano A (2004) Subcutaneous dextrose for rehydration of elderly patients – an evidence-based review. BMC Geriatrics 4 (2)

Watson, M et al (2009) Oxford Book of Palliative Care 2nd edition. Oxford University Press

7. APPENDIX 1: CONSULTATION SUMMARY

Those listed opposite have been consulted and comments/actions incorporated as required	Groups and/or individuals consulted
	Palliative Care CNSs
	Consultant in Palliative Medicine
	Community Services Matron
	Dr Sarah Hay, EOLC Lead GP
	Community Care Team Leaders
	Policy Review Group
	Clinical Risk Management Group
	Area Prescribing Committee
	Health Records Committee

8. APPENDIX 2: ASSESSMENT OF COMPETENCY DOCUMENT

Competency Statement: Can maintain patients' safety while administering subcutaneous fluids (Competency is: *the skills and ability to practice safely and effectively without the need for direct supervision. NMC*)

Name:	Job Title:
Department:	Ext Number:
Trained By:	Date:
	Signature:

Method of Assessment: Self-assessment of competency in the use of medical device in relation to defined key elements and countersigned by appropriate member of staff (Key Trainer, Manager, Educator, Mentor etc).

	Competency	Achieved
1	State the clinical indications for subcutaneous fluid administration	
2	Show awareness of procedure	
3	Explain safety check prior to use	
4	Identify appropriate equipment needed for set up	
5	Demonstrate understanding of infusion rate calculation and ability to check this	
6	Demonstrate the correct procedure for initial set-up, initiating and commencing an infusion safely. Including as follows: <ul style="list-style-type: none"> • Prepare the fluid, attach the giving set and manually prime the line. • Review, confirm and calculate the drip rate • Connect line to patient • Start infusion • Check the infusion is running • Continual monitoring of infusion 	
7	Demonstrate the awareness and understanding of infusion monitoring and documentation:	
8	Demonstrate ability to dismantle the infusion correctly on completion of infusion	
9	Is aware of the need for decontamination as per Trust's procedure	
10	Demonstrate awareness of effects and side effects of subcutaneous fluids and site reactions to check for during monitoring	
11	Will ensure correct storage and safe-keeping of equipment	

Disclaimer:
 (i) Having answered YES to the above key statements and taken into account my personal assessment of my competence in the use of the medical device, I declare that I am competent to use the device safely as per the Trusts' guidelines.
OR
 (ii) I require further training in the use of this equipment in order to reach a competent level of practice and will discuss these needs with my Mentor/Ward Manager/ Trainer/Equipment Controller.

I certify that is competent in the administration of subcutaneous fluids

Signed: Position: Date:

9. APPENDIX 3: SUBCUTANEOUS FLUID SITE MONITORING CHART

SUBCUTANEOUS FLUID SITE MONITORING CHART

Allergies and Adverse Drug Reactions – (write NKDA if none)				Name Address NHS NUMBER GP
Medicines must NOT be administered until this section has been completed				
Medicines/Substance	Reaction	Sign (NAME)	Date	
Allergy status unconfirmed. Authority to administer medicines Ceases after 24 hours		Sign (NAME)	Time & Date	

Initial set-up **Date**.....**Time**..... **By**.....

Signature.....

Fluid prescribed **Volume**..... **Rate**

Saf-t-intima Site..... **Date of last site change**.....

Date								
Time								
Site Position								
Site Condition: red, tender, bruised, leakage, bleeding, pain, oedema, inflammation, swelling, If any of above consider site change.								
Respiratory tract secretions? Absent, minimal, moderate, severe If RTS present review Fluid								
Signature								

Date								
Time								
Site Position								
Site Condition: red, tender, bruised, leakage, bleeding, pain, oedema, inflammation, swelling, If any of above consider site change.								
Respiratory tract secretions? Absent, minimal, moderate, severe If RTS present review Fluid								
Signature								

When considering appearance please use the following guideline.

Site appears intact with no pain on palpation, redness, swelling or oozing	Continue infusion
Slight pain on palpation and/or redness, swelling or oozing to a diameter of less than 0.5cm	Continue infusion. Check site more frequently
Pain on palpation and or redness, swelling or oozing to a diameter of between 0.5cm and 2cm	Discontinue infusion. Resite if appropriate and monitor frequently until symptoms diminish
Pain on palpation and/or redness, swelling or oozing to a diameter of greater than 2cm	Discontinue infusion. Resite if appropriate and monitor frequently until symptoms diminish and apply dressing if required.

